Efficacy and safety of telitacicept in patients with progressive interstitial lung disease associated with antisynthetase syndrome, rheumatoid arthritis, or Sjögren’s syndrome: a prospective observational study

Telitacicept demonstrated significant clinical efficacy and a favorable safety profile in patients with ILD associated with antisynthetase syndrome, rheumatoid arthritis, and Sjögren's syndrome. These findings suggest telitacicept may be a promising therapeutic option for refractory or complex connective tissue disease-associated ILD.